Search results
Immunotherapy to treat cancer gave rise to 2nd cancer in extremely rare case
LiveScience· 2 days agoIn an extremely rare case, a patient who received a cell-based cancer treatment later developed a...
Unequal access to cancer breakthrough | Philly Health Insider
Philly.com· 4 days agoThis week, we have a deep dive into racial disparities in the Penn-developed cancer treatment CAR-T...
Study Elucidates Skin Signs of VEXAS Syndrome
Medscape· 2 days agoSkin manifestations are common in the vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome and present early in the disease course....
Mouth Ulcer
Health via Yahoo News· 22 hours agoMouth ulcers that last for too long can cause other conditions like cellulitis or a bacterial infection. Chronic mouth ulcers could be an early sign of a...
SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-cell...
Digital Journal· 5 days agoThis type of engineered T -Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This breakthrough method for immunotherapy against cancer is normally...
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains | Investing.com
Investing.com· 1 day agoStocks Analysis by The Tokenist (Timothy Fries) covering: Pfizer Inc, Ocuphire Pharma Inc, Rocket...
Lantern Pharma secures Japan patent for cancer drug By Investing.com
Investing.com· 4 days agoLantern Pharma Inc. (NASDAQ:LTRN), a company leveraging artificial intelligence (AI) in cancer ...
Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing
Zacks via Yahoo Finance· 3 days agoIt makes it possible for medical practitioners to determine which patients have advanced ovarian ...
Biotech Catapults On 'Unprecedented' Results For Gel-Based Drug
Investor's Business Daily· 2 days agoAfter three months, 79.6% of patients treated with UroGen Pharma's (URGN) drug had a complete...
FDA Expands Repotrectinib Label
Medscape· 3 days agoThe new accelerated approval for the TKI was based on the overall response rate in 48 patients.